U.S. Health Care REITs Stock News

NYSE:CADE
NYSE:CADEBanks

Cadence Bank (CADE) Margin Slip To 28.6% Tests Bullish Growth Narrative

Cadence Bank (CADE) has put up a clean set of FY 2025 numbers, with fourth quarter revenue at US$500.4 million and EPS at US$0.76, while trailing twelve month revenue came in at US$1.9 billion and EPS at US$2.83. Over recent periods the bank has seen revenue move from US$435.7 million in Q4 2024 to US$500.4 million in Q4 2025, with quarterly EPS stepping from US$0.70 to US$0.76. This sets the stage for investors to focus on how consistently the bank converts that income into margins and long...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record

If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned 3.1% over the last 7 days and 16.6% over the last 30 days, while the 1 year return sits at negative 19.0%. This can catch the eye of investors thinking about changing risk and return trade offs. Recent coverage of Agios has focused on its position within the pharmaceuticals and biotech space and...
NasdaqGS:NVAX
NasdaqGS:NVAXBiotechs

Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus

Novavax (NasdaqGS:NVAX) has signed a licensing agreement with Pfizer covering the use of its Matrix-M adjuvant technology in up to two infectious disease areas. The deal includes upfront payments to Novavax, with the potential for future milestone payments and royalties tied to Pfizer’s use of Matrix-M. The agreement signals industry interest in Novavax’s adjuvant platform and introduces new potential revenue channels alongside its own vaccine programs. For you as an investor, this puts...